These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37639050)

  • 1. A novel germline hyperactivating JAK2 mutation L604F.
    Dvořáček L; Marková J; Holoubek A; Grebeňová D; Kundrát D; Kuželová K; Schwarz J
    Ann Hematol; 2023 Oct; 102(10):2725-2734. PubMed ID: 37639050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel germline JAK2
    Song J; Lanikova L; Kim SJ; Papadopoulos N; Meznarich J; Constantinescu SN; Parsegov B; Prchal JF; Prchal JT
    Am J Hematol; 2024 Jul; 99(7):1220-1229. PubMed ID: 38629639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
    Dusa A; Mouton C; Pecquet C; Herman M; Constantinescu SN
    PLoS One; 2010 Jun; 5(6):e11157. PubMed ID: 20585391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
    Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
    Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.
    Kapralova K; Horvathova M; Pecquet C; Fialova Kucerova J; Pospisilova D; Leroy E; Kralova B; Milosevic Feenstra JD; Schischlik F; Kralovics R; Constantinescu SN; Divoky V
    Blood; 2016 Sep; 128(10):1418-23. PubMed ID: 27389715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
    Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
    Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience.
    Sultan S; Irfan SM; Khan SR
    Asian Pac J Cancer Prev; 2016; 17(3):1053-5. PubMed ID: 27039724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
    Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
    Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
    Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
    Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.
    Yoshinaga K; Mori N; Wang YH; Tomita K; Shiseki M; Motoji T
    Int J Hematol; 2008 Jul; 88(1):82-87. PubMed ID: 18528646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses.
    Suessmuth Y; Elliott J; Percy MJ; Inami M; Attal H; Harrison CN; Inokuchi K; McMullin MF; Johnston JA
    Br J Haematol; 2009 Nov; 147(4):450-8. PubMed ID: 19735488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
    Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
    Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.